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A B S T R A C T   
A point-of-care (POC) device to enable de-centralized diagnostics can effectively reduce the time to treatment, 
especially in case of infectious diseases. However, many of the POC solutions presented so far do not comply with 
the ASSURED (affordable, sensitive, specific, user-friendly, rapid and robust, equipment free, and deliverable to 
users) guidelines that are needed to ensure their on-field deployment. Herein, we present the proof of concept of 
a self-powered platform that operates using the analysed fluid, mimicking a blood sample, for early stage 
detection of HIV-1 infection. The platform contains a smart interfacing circuit to operate an ultra-sensitive 
electrolyte-gated field-effect transistor (EGOFET) as a sensor and facilitates an easy and affordable readout 
mechanism. The sensor transduces the bio-recognition event taking place at the gate electrode functionalized 
with the antibody against the HIV-1 p24 capsid protein, while it is powered via paper-based biofuel cell (BFC) 
that extracts the energy from the analysed sample itself. The self-powered platform is demonstrated to achieve 
detection of HIV-1 p24 antigens in fM range, suitable for early diagnosis. From these developments, a cost- 
effective digital POC device able to detect the transition from “healthy” to “infected” state at single-molecule 
precision, with no dependency on external power sources while using minimal components and simpler 
approach, is foreseen.   
1. Introduction 
Widespread diagnosis is crucial for early detection and treatment, 
particularly in case of infectious diseases such as human immunodefi-
ciency virus (HIV), tuberculosis, malaria, Ebola etc., that have been 
leading causes of death in resource limited locations (Maffert et al., 
2017). For instance, an early detection of p24 antigens that make up the 
HIV viral core would ensure proper antiretroviral therapy for effective 
immune response and prevent vulnerable opportunistic infections (Kahn 
and Walker, 1998). The host serum in the first acute phase of HIV 
infection contains from 10 to 3000 virions mL  1, with an estimated p24 
concentration of around 50 aM to 15 fM (Rissin et al., 2010). Though, 
polymerase chain reaction based ribonucleic acid test (Adler et al., 2008; 
Hecht et al., 2002) has proven to be a suitable diagnostic tool in the first 
acute phase, the need for expensive equipment and reagents highly 
impact their global outreach (Barlow et al., 1997; Kosaka et al., 2017). 
Moreover, the approach often involves a tedious routine of sample 
extraction and operation in suitable laboratories for analysis. This 
together with the involved cost, resources and the long assay procedures 
does not comply with ASSURED (affordable, sensitive, specific, 
user-friendly, rapid and robust, equipment free, and deliverable to 
users) characteristics defined by the World Health Organization (Maffert 
et al., 2017; Plate and Rapid, 2007) towards the objective of delivering 
required diagnostic aid to resource-limited settings. 
Thereby, different sensing strategies towards obtaining point-of-care 
(POC) devices for a rapid, highly sensitive response and quantitative 
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digital information through a simple operation have been assessed in the 
last few years. Techniques based on enzyme-linked immune sorbent 
assay (ELISA) employing Au nanoparticles (Lee et al., 2004) and DNA 
barcodes (Tang and Hewlett, 2010) have significantly pushed the HIV-1 
p24 detection limit to less than 0.5 pg mL  1. Even better results have 
recently been acquired with molecularly imprinted polymer based 
electrochemical sensor (Ma et al., 2017). Specially promising are the 
bioelectronic label-free sensors based on an electrolyte-gated organic 
field-effect transistor (EGOFET) (Tobjork and Osterbacka, 2011; Torsi 
et al., 2013). EGOFETs are field-effect transistors that involve an ionic 
conducting electrolyte as dielectric and connects the transducing gate 
electrode (optionally detachable) with an organic semiconductor-based 
channel. With effective capacitive coupling between gate/electrolyte 
and electrolyte/semiconductor interfaces, these offer excellent sensi-
tivities and sub-volt operation that could be potentially achieved with 
low power sources like fuel cells and batteries. These are endowed with 
selectivity via the integration of suitable bio-recognition elements and 
have lately exhibited sensitivities capable of single molecule detection 
(Macchia et al. 2018a, 2018b; Tobjork and Osterbacka, 2011). The key 
to this Single-Molecule detection with a Transistor or SiMoT (Macchia 
et al., 2018a), is the immobilization of trillions of capturing antibodies 
on a millimeter-sized gate. The extremely large number of capturing 
sites covalently attached to a large interface, addressed as wide-field 
sensing approach (Gooding and Gaus, 2016), increases the interaction 
cross-section with the biomarker to be detected, allowing the assay of 
extremely diluted solutions. At the same time, a cooperative effect, 
enabled by a hydrogen-bonding network and fuelled through operating 
gate voltage, amplifies the impact of a single or of few bindings, that can 
be detected as a sizable variation of the transistor channel current 
(Macchia et al. 2018a, 2019a). Recently, the SiMoT approach has been 
proposed also for detection of HIV-1 p24 at the single molecule limit 
(Macchia et al., 2019b). This disruptive technology that promises a 
simple operation offers biosensing capabilities comparable to 
state-of-the-art label-free single-molecule sensors based on nano-scale 
devices. Additionally, in contrast to the nanotechnology-based sys-
tems, the SiMoT platform can be fabricated via solution-processed 
scalable procedures that are foreseen to be developed into a low-cost, 
large-area printed technology (Tobjork and Osterbacka, 2011). How-
ever, despite salient features that make SiMoT platforms as promising 
candidates for ASSURED POC devices, no efforts have been made so far 
towards the integration of these sensing components to demonstrate a 
portable standalone device operation without the need of dedicated 
electronic equipment. 
Herein, we present a self-powered platform containing a smart 
interfacing circuit for the operation of an ultra-sensitive bioelectronic 
sensor that allows selective detection of the HIV-1 p24 antigen at 1 fM 
concentration with a hand-held multimeter. The platform involves the 
use of minimal and low-cost electronic components, and achieves self- 
powered operation by using a compact paper-based glucose biofuel 
cell (BFC) that is able to activate with a small volume (3.5 μL) of the 
biological sample being analysed (Fig. 1). The current approach is a 
significant step forward to the standalone POC bioelectronic devices 
with relevant opportunities for ultrasensitive detection of biomarkers, 
that could have a terrific impact on the public health. 
2. Material and methods 
The details about the materials used, fabrication and operation of 
EGOFET, bio-functionalization of the gate electrode, design and as-
sembly of paper-based BFC, electrodes and electrolyte preparation, 
paper-based BFC operation, self-powered diagnostic platform and the 
estimation of current through it are present in the Supplementary 
Information. 
3. Results and discussion 
3.1. p24 antigen sensing response analysis of EGOFET using a 
semiconductor parameter analyzer 
The detection platform for HIV-1 p24 protein rely on a poly (3- 
hexylthiophene-2,5-diyl), P3HT organic semiconductor based EGOFET 
(Fig. 2a) that consisted an Au gate tagged with the capturing probe anti- 
HIV-1 p24. With water (HPLC grade deionised) as gating electrolyte, the 
output characteristics (Fig. 2b) of typical EGOFET, measured using a 
bare Au gate, revealed drain current (ID) modulation with linear and 
active regions for the applied drain voltages (VDS) at a given gate po-
tential (VGS). A negligible hysteresis of ID was showed by the EGOFET 
when VDS was cycled in increasing and decreasing values. Also from the 
characteristics, field-effect based operation at biasing voltages less than 
1 V (VDS, VGS) with ID in the order of hundreds of nA to tens of μA is 
clearly evident. However, in order to operate the EGOFET as a gate 
voltage controlled current source (active region), VDS was fixed at   0.5 
Fig. 1. Schematic illustration of the approach towards development of an ultrasensitive self-powered bioelectronic platform. The self-powered platform performed 
operation of the EGOFET through conjugating a paper-based BFC that is activated from the sample being analysed. A suitable interfacing circuit promoted an on- 
demand detection of the biomarkers and easy readout using a handheld multimeter. 
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V during measurement of transfer curves in the subsequent steps. 
As a proof of concept, the detection of a 1 fM concentration of HIV-1 
p24 proteins was targeted in development of the screening assay that 
suits to asses an individual in the initial phase of the infection, where the 
estimated concentration of p24 proteins is known to be between 50 aM 
to 15 fM. For this, the surface of the bare Au gate as shown in Fig. 2a was 
bio-functionalized with anti-HIV-1 p24 antibodies, through a chemical 
self-assembled monolayer (chem-SAM). To minimize non-specific in-
teractions, the gate was further packed with bovine serum albumin 
(BSA) to fill the spaces left after the conjugation. The transfer curves 
measured using this bio-functionalized gate, after its incubation in PBS 
standard-solutions containing 1 fM HIV-1 p24 proteins, indicated a 
change in ID from the reference curve obtained prior using the same gate 
incubated in only PBS (Fig. 2c). However, when measurements were 
taken for similar experiments with a solely BSA functionalized Au gate 
electrode to capture HIV-1 p24 proteins, no such variation in ID was 
observed (Fig. 2d). It may be noted that BSA do not bind to HIV-1 p24, 
thus serves as a negative control experiment. The transfer characteristic 
curves also indicated a shift in threshold voltage (VT) due to the bio- 
functionalization when compared to that acquired using a bare Au 
gate as reported previously (Macchia et al., 2018a). In case of anti-HIV-1 
p24/BSA functionalized Au gate, a VT of - 0.20  0.05 V was observed, 
while a VT of   0.12  0.05 V was measured with the bare Au gate. Thus, 
it can be inferred from the transfer curves that the EGOFET’s response is 
specific to the antigen-antibody interaction of HIV-1 p24 proteins. 
The relative current change in ID upon exposure of the gate electrode 
to the target analyte in the PBS solutions is typically used as the sensing 
response (Eq. (1)), 
Sensing Response  ΔIIo

I   Io
Io
(1)  
where Iₒ and I denote the current values obtained before and after the 
exposure to the sample solution. It was observed that the response ob-
tained with an anti-HIV-1 p24/BSA functionalized Au gate was clearly 
distinct in comparison to the solely BSA functionalized Au gate electrode 
(Fig. 3a). The overall response change between them is given by Eq. (2), 
Response change % 
ΔIa
Ioa
 
ΔIb
Iob

 100 (2)  
where subscript a, b corresponds to measurements with solely BSA and 
anti-HIV-1 p24/BSA functionalized Au gate electrodes respectively. As 
further indicated by the characteristics in Fig. 3b, the biosensor showed 
a 50% difference in response between the two bio-functionalized gates 
at VGS values between   0.1 V and   0.3 V, which is a wide operational 
zone of sensing that provides robustness in terms of designing suitable 
interfacing electronics. 
3.2. Smart interfacing circuit for BFC-EGOFET integration 
The driving of the EGOFET has been assessed by designing a smart 
interfacing circuit (Fig. 4a) to bias all the sensing steps (described in 
section 3.1). Unlike the traditional approach involving scanning of VGS, 
as performed with a semiconductor parameter analyzer to obtain the 
transfer curves (Fig. 2c and d), the interfacing circuit operates the 
EGOFET at a fixed VGS, VDS and yields a specific output voltage readable 
by a handheld multimeter without the need for complex instrumenta-
tion. Moreover, the circuit uses the power generated by a glucose fuel 
cell to set the EGOFET at the operating point and provide the required 
current for stable operation. 
Hence, it was essential to initially derive this optimum operating 
voltage for VGS and VDS. We selected the value of VGS to be   0.3 V based 
on two criteria: (i) it has to be a voltage lower than all the threshold 
voltages recorded along the different sensing steps (the minimum value 
of VT corresponded to   0.2 V in case of HIV-1 p24 functionalized Au 
gate) and (ii) it has to provide a response change of at least 50% between 
the two bio-functionalized gates. (Fig. 3). The open circuit voltage 
(OCV) of BFC, employing FAD-GDH as the primary constituent of the 
anode and silver oxide as cathode was measured to be about 0.85 V 
Fig. 2. (a) The three-dimensional schematic 
structure of the EGOFET employed for HIV-1 
p24 antigen detection along with the 
sketches of the proteins used. (b) Output 
characteristics (ID vs. VDS) of the fabricated 
EGOFET measured using a bare Au gate. (c, 
d) Transfer characteristics (ID vs. VGS at VDS 
   0.5 V) for anti-HIV-1 p24/BSA and 
solely BSA functionalized Au gate before and 
after the interaction with HIV-1 p24 antigens 
(1 fM). A distinct change in characteristics 
was observed in case of anti-HIV-1 p24/BSA 
functionalized Au gate upon specific inter-
action with HIV-1 p24 antigens.   
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when fed with a PBS solution containing 5 mM glucose as electrolyte 
(generally accepted as the average glucose content in blood under 
fasting condition). As shown in Fig. 4a, if VBFC is considered to be the 
voltage supplied by the BFC, then the required VGS (given by Eq. (3)) of 
  0.3 V was achieved by connecting a voltage divider formed through 
resistors R1 and R2, selected as 1.8 MΩ and 3.3 MΩ respectively. R1 and 
Fig. 3. (a) The response curve indicating the relative changes in ID (ΔI/Io) for a series of VGS at VDS    0.5 V upon exposure to HIV-1 p24 protein (1 fM) in case of 
anti-HIV-1 p24/BSA and solely BSA functionalized Au gate electrode when biased using an external power supply. (b) The overall change in the sensing response 
obtained between solely BSA and anti-HIV-1 p24/BSA functionalized Au gates, at different VGS (for VDS    0.5 V) for the detection of 1 fM concentration of HIV-1 
p24 protein. 
Fig. 4. (a) Interfacing circuit for standalone operation of EGOFET with paper-based BFC for HIV-1 p24 detection. (b) Scheme illustrating the structure of paper-based 
BFC used for standalone operation of the EGOFET. The power was generated from the analysed sample absorbed on paper, that is sandwiched between screen-printed 
anode and cathode electrodes. (c) Polarization curve of paper-based BFC operated with a PBS solution containing 5 mM glucose solution at a scan rate of 1 mV s  1. 
The potential across BFC was approximately around 0.845 V at the maximum operating current of 1.1 μA required for EGOFET operation. (d) Voltage across paper- 
based BFC operated with a PBS solution of 5 mM glucose while suppling a current of 2 μA (chronopotentiometry curve). The data in (c, d) are represented as an 
average with respective standard deviations of measurements made using three independent, identical paper-based BFCs. 
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R2 were set to be within the range of MΩ to minimize the current de-
mand of the voltage divider to the BFC. 
VGS    VBFC
 R1
R1R2

(3) 
VDS can be easily applied by connecting the BFC terminals directly 
across the drain and source terminals of EGOFET (VBFC  -VDS). How-
ever, in order to extract a measurable output voltage (Vout) corre-
sponding to the ID flowing through the EGOFET, we incorporated a 
series resistor, RD. The addition of RD will introduce variations in VDS 
that depend on the ID flowing through the EGOFET conducting channel 
during different sensing steps (see Eq. (4)). 
VDS    VBFC IDRD (4) 
Therefore, despite the anticipated deviations in VDS through placing 
of RD, any influence in the output current ID can be avoided by keeping 
EGOFET operational voltages in the active region, where the sensing 
parameter ID is tuned only by VGS (which is already fixed at   0.3 V). This 
condition is reached when VDS  VDS(sat), for all the steps involved in the 
sensing operation, being VDS(sat)  VGS – VT. In the current experiment, 
the maximum value recorded for VT was   0.12 V (in case of bare Au 
gate) and therefore, considering VDS(sat) to be at around   0.18 V ensures 
the EGOFET operation in active region for all the sensing steps involved 
in the measurement protocol. In order to keep VDS value below   0.18 V, 
it is desirable to ensure that the voltage drop across RD at the highest 
magnitude of drain current (ID(max)) is kept below a certain value. 
Considering the transfer curves in Fig. 2c and d obtained for different 
steps, the maximum magnitude of drain current recorded when char-
acterizing the EGOFET with the semiconductor parameter analyser was 
observed to be ~   435 nA (with anti-HIV-1 p24 functionalized Au gate). 
In order to avoid boundary operation, we provided a safety margin of 
about 100%, and decided to set ID(max) value to   900 nA (twice the 
anticipated current). This limited the RD  745 kΩ (from Eq. (4)) to bias 
the EGOFET at an operational voltage of VDS    0.18 V (VDS(sat)). 
However, for the present case, the operating point of VDS (  0.4 V) was 
chosen to be well beyond the active region threshold (VDS(sat)), which set 
the value of RD to be 500 kΩ. Importantly, the value of RD in the order of 
kΩ allows to generate voltage readouts across it in the mV range, that 
can be easily measured with a handheld multimeter. Thereby, the circuit 
not only interfaces for standalone operation of EGOFET, but further 
generates a convenient method of measuring the output. This greatly 
simplifies the application of EGOFET and makes it more amicable for 
POC platforms.  
3.3. Characterization of paper-based BFC 
The paper-based BFC was developed considering the voltage and 
current requirements for the independent operation of EGOFET. The 
paper-based BFC proposed here is intended to be prospectively fed with 
the same biological sample that is to be analysed, which releases the 
need of connecting the platform to an external power supply and renders 
the system to be completely autonomous. Due to the limited available 
volume of sample to perform the test (blood drop coming from a finger 
prick ranges from 0.3 μL to 50 μL), the BFC was developed to operate 
with a minimum volume of 3.5 μL of sample solution. The cell design 
parameters, choice and concentration of electrode materials were opti-
mised to obtain the required power levels from this limited amount of 
sample. The BFC with a sandwich type layout (Fig. 4b), used 5 mM 
glucose solution (contained in PBS) as electrolyte that was placed on a 
glass-fiber-paper. An open circuit voltage (OCV) of about 0.85 V was 
generated by the paper-based BFC. Additionally, the polarization curve 
showed a peak current of 4.15  0.11 μA and a maximum power of 3.36 
 0.06 μW (Fig. 4c). Taking into account the maximum current expected 
to flow across the transistor channel and the equivalent impedance of 
the voltage divider, we estimated that the entire circuit would require 
the paper-based BFC to provide a stable current of at least 1.1 μA (refer 
to Estimation of current for operation of the self-powered platform in SI, 
Fig. S1). According to the polarization curve, the potential across BFC 
corresponding to this current was expected to be approximately around 
0.845 V. Thereby, it was evident from the OCV and the polarization 
curve that the paper-based BFC is capable of supplying the required 
voltage in the range of EGOFET operation. The effect on the perfor-
mance of BFC for other extreme concentrations of glucose, say 2.5 and 
10 mM (corresponding to hypoglycaemia and hyperglycaemia condi-
tions) were also analysed using the polarization curves. The changes 
(ΔV) in supply voltage (VBFC) from the OCV at these concentrations were 
found to be identical below the required maximum current of 1.1 μA 
(Fig. S2). This showed the BFC’s ability to operate at a wide range of 
glucose concentrations commonly observed in patients. The voltage 
stability of BFC over time was examined through chronopotentiometry 
measurements (Fig. 4d) while delivering a current of about 2 μA. It was 
observed that the BFC maintained a stable voltage with deviation less 
than 0.001, 0.005 and 0.01 V for at least 75, 100 and 120 s respectively. 
The influence of this voltage drop on the operating voltage VGS of 
EGOFET was found to be less than 0.005 V (from Eq. (3)) in the initial 
120 s. The transfer characteristics of EGOFET (Fig. 2c and d) indicated 
that any deviation caused in VGS within 0.01 V (caused from a VBFC 
change of 0.028 V) from the operating point of   0.3 V results in a 
response change (from Eq. (2)) of 48% and higher between the two bio- 
functionalized gates. Further, for 300 s of continuous operation that 
caused a maximum change of   0.04 V in VGS, a response change of at 
least 32% can still be assured to detect HIV-1 p24 antigen despite a 
maximum deviation of 0.1 V in VBFC. 
However, when EGOFET is biased, its response is quick (<1 s) and 
the output voltage appears rather instantaneously. So, during any of the 
sensing steps, it is enough to acquire a single output voltage measure-
ment within the first few seconds (preferably before 120 s) to register the 
bio-interaction occurred on the gate surface. This interval is more than 
convenient to acquire a digital measurement easily with a simple 
multimeter. 
3.4. Standalone operation of EGOFET for detection of HIV-1 p24 
The proof-of-concept of a self-powered diagnostic platform was built 
connecting the paper-based BFC and the EGOFET through the smart 
interfacing circuit. A photograph of the setup is featured in Fig. 5a. The 
sensing measurements were performed by monitoring ID and Vout values 
using the anti-HIV-1 p24/BSA functionalized Au gate, before and after 
exposure to a 1 fM concentration of HIV-1 p24 protein solution (Fig. 5b 
and c). Similar set of negative control experiments were also carried out 
using the Au gate functionalized with solely BSA (Fig. 5d and e). Indeed, 
very stable voltages (and currents) were acquired and a distinct change 
in Vout (and ID) was recorded for the control and sensing experiments. 
Further, the measured voltages in the range of mV were easily obtained 
with a handheld multimeter. As RD is a fixed value, the sensing response 
(Eq. (1)) and the response change (Eq. (2)) can be calculated directly by 
substituting the measured Vout in place of ID for the respective sensing 
step. The relative changes (ΔV/Vo) in Vout upon exposure to the target 
marker during standalone operation of EGOFET returned values of 
  0.46  0.03 and 0.04  0.02 in case of HIV-1 p24/BSA and solely BSA 
functionalized Au gates respectively. Here, Vo and V correspond to 
voltage measured across RD before and after the exposure to the analyte 
solution. The ΔV/Vo values obtained in standalone operation were in 
good agreement with the data gathered using semiconductor parameter 
analyser when EGOFET was biased externally (Fig. 5f). Moreover, 
despite the variations in recorded output voltages for different EGO-
FETs, the interfacing circuit allowed to decipher the differences in 
response (Fig. S3). The observed results further proved the very high 
response reproducibility of the proposed platforms. 
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4. Conclusions 
This work presents an approach to a standalone operation of an 
EGOFET through a self-powered smart sensing platform. The low 
operational voltages and currents required for EGOFET working allow 
the use of glucose BFC as the sole power source to drive it through a 
smart interfacing circuit that yields output voltages readable with a 
handheld multimeter. In fact, a small volume (3.5 μL) of the analysed 
sample prove to be enough for the BFC to reliably deliver a stable output 
voltage for a sufficient time to acquire a digital measurement. Interest-
ingly, the self-powered platform detects the presence of HIV-1 p24 
proteins at a concentration of 1 fM, and is promising for the POC based 
diagnosis of early stage HIV-1 infection. While bulky, complex and 
expensive equipment have been generally required to obtain EGOFET 
response based on drain current (in order of nA), the circuit in the 
current work provides a output voltage (in mV range) that can be easily 
measured with a portable handheld multimeter to obtain similar results. 
The circuit is built with a minimum number of passive electronic com-
ponents that present the capability of achieving a completely printable 
biosensing device applicable for the detection of a wide spectrum of 
clinically relevant biomarkers at an affordable cost. In a view to provide 
a decentralized approach to diagnostics, the proposed self-powered 
platform is a crucial development and could initiate relevant opportu-
nities in the field of ultrasensitive POC testing, particularly in rural 
locations. 
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